Medicines Development Ltd.

What Medicines Development Ltd. does

Medicines Development Ltd., operating as Medicines Development for Global Health (MDGH), is an Australian not-for-profit biopharmaceutical company founded in 2005 by Mark Sullivan. The company develops and registers treatments for neglected tropical diseases (NTDs) — including river blindness (onchocerciasis), scabies, leprosy Type 2 reaction, lymphatic filariasis, soil-transmitted helminth infections, strongyloidiasis, and rotavirus — that affect over one billion people in low-income endemic countries with little or no commercial market incentive. Its core assets are the small-molecule anti-parasitic moxidectin (FDA-approved for onchocerciasis in 2018, with a 2024 pediatric label expansion to patients aged four and above, and listed on WHO Essential Medicines Lists), the in-licensed dovramilast for leprosy Type 2 reaction (FDA orphan drug designation and IND clearance), and the RV3 human neonatal rotavirus vaccine developed with Murdoch Children's Research Institute. The company runs Phase 1-3 clinical trials and sponsors programs such as a fully enrolled Phase 2b moxidectin-in-scabies study and a fully enrolled Phase 3b/4 moxidectin-vs-ivermectin comparative study in river blindness.

MDGH operates a nonprofit revenue model rather than a traditional commercial sales model. Income is generated primarily through government and institutional grants — including a US$10 million investment from the Global Health Investment Fund, US$4.9 million and US$1 million US government grants, an AUD$1.3 million Victorian Government grant, and a 6-8 million Wellcome Trust UK seeding drug discovery award — supplemented by philanthropic donations and a one-time Priority Review Voucher (PRV) sale to Novo Nordisk disclosed in company materials. Finished product is distributed at minimal or no cost through the WHO Essential Medicines Program, endemic country health ministries, and mass drug administration (MDA) campaigns rather than via commercial pharmacy channels. The organization is headquartered in Melbourne with offices in the UK and US and a new clinical study site in Côte d'Ivoire, and is embedded in global health governance as a founding member of the Clinical Trials Community Africa Network, a foundation member of the Global Health Alliance Melbourne, an official World NTD Day partner, and a member of the WHO GAP-f pediatric formulations network.

Name

Medicines Development Ltd.

Legal name

Medicines Development for Global Health Ltd.

Website

https://medicinesdevelopment.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Medicines Development for Global Health (MDGH) is an Australian not-for-profit biopharmaceutical company founded in 2005 that develops and registers treatments for neglected tropical diseases, including the FDA-approved anti-parasitic moxidectin for river blindness, serving endemic country governments, WHO programs, and global health agencies.

Ownership category

akta.pro rank

Product category

Neglected Tropical Disease Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

akta.pro secondary industry

Disease-Specific Global Initiatives (HIV/TB/Malaria/NTDs) (HLAJAOAE)

Keywords

• Neglected tropical disease therapeutics
• Antiparasitic drug development
• Global health pharmaceuticals
• Vaccine development
• FDA approved medicines

Headquarters

HQ city

Southbank

HQ country

Australia

HQ region

Oceania

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Grants and Funding: Primary revenue stream from government grants (Victorian government, US government), international donors, and foundations including Wellcome Trust for drug development programs
2. Priority Review Voucher Sales: Sale of Priority Review Vouchers (PRVs) earned through FDA approval of moxidectin; disclosed Novo Nordisk as purchaser of one PRV at record amounts
3. Donations and Philanthropy: Charitable donations from individuals and institutional donors supporting global health mission

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Medicines Development Ltd. (operating as Medicines Development for Global Health, MDGH) is an Australian not-for-profit biopharmaceutical company that develops and registers new medicines for neglected tropical diseases (NTDs). Its lead product is moxidectin, an oral anti-parasitic FDA-approved for river blindness (onchocerciasis) and under development for scabies, with additional programs including dovramilast for leprosy Type 2 reaction and a neonatal rotavirus vaccine.

Product overview

Medicines Development Ltd. is a pharmaceutical development organization focused on neglected tropical diseases (NTDs). The company's product portfolio centers on three key investigational/experimental treatments: Moxidectin (an anti-parasitic for river blindness and scabies, with FDA approval for onchocerciasis), Dovramilast (an in-licensed treatment for leprosy Type 2 reaction), and the RV3 rotavirus vaccine developed in partnership with MCRI. The company operates a pipeline-driven R&D model with clinical trial operations across multiple disease areas including lymphatic filariasis, soil-transmitted helminth infections, strongyloidiasis, and tuberculosis.

Differentiator

Problem solved

Functional benefit

Products and services

• Moxidectin Oral anti-parasitic medication approved by the FDA for the treatment of river blindness (onchocerciasis) and under clinical development for scabies, lymphatic filariasis, and other neglected tropical diseases; distributed through WHO programs and mass drug administration campaigns.
• Dovramilast Investigational treatment for leprosy Type 2 reaction (erythema nodosum leprosum), in-licensed from Amgen; received FDA orphan drug designation and IND clearance.
• RV3 Rotavirus Vaccine Human neonatal rotavirus vaccine developed in collaboration with Murdoch Children's Research Institute (MCRI); proven effective in clinical trials and published in NEJM.

Quantifiable outcome

• Moxidectin approved by FDA for river blindness June 2018, with expanded indication for children as young as 4 years
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core, major and minor.

• AmgencoreStrategic or Co-development PartnerMDGH announced in-licensing of investigational treatment for TB and leprosy from Amgen. Received FDA orphan drug designation for dovramilast to treat leprosy Type 2 reaction.
• Atticus MedicalcoreStrategic or Co-development PartnerClinical collaboration to enroll first patient in Phase 2b study of moxidectin in scabies. MDGH is the sponsor of the clinical program.
• Monash UniversitycoreStrategic or Co-development PartnerMonash University and MDGH team up to tackle gut infections, including rotavirus vaccine research collaboration.
• Murdoch Children's Research Institute (MCRI)coreStrategic or Co-development PartnerMDGH employee joined the RV3 rotavirus vaccine team at MCRI. Collaborative research on human neonatal rotavirus vaccine published in NEJM.
• World Health Organization (WHO)coreStrategic or Co-development PartnerMDGH is official partner for World NTD Day; joined WHO's Global Accelerator for Paediatric Formulations GAP-f network; moxidectin included on WHO Essential Medicines Lists.
• Ragon Institute of MGH, MIT and HarvardmajorStrategic or Co-development PartnerCollaborator Dr. Bruce D. Walker, Director of Ragon Institute, featured in Nature publication. Collaborative research relationship.
• Global Health Alliance MelbournecoreOthersMDGH is a foundation member of the Global Health Alliance Melbourne, collaborating with other Australian global health organizations.
• Clinical Trials Community Africa NetworkcoreStrategic or Co-development PartnerMDGH is a founding member of the Clinical Trials Community Africa Network, supporting clinical trial infrastructure in Africa.
• Neglected Tropical Disease NGO NetworkminorStrategic or Co-development PartnerMDGH joined the NTD NGO Network for collaboration on neglected tropical disease advocacy and programs.
• Auckland UniServicesminorStrategic or Co-development PartnerMDGH Founder Mark Sullivan joins the Investment Committee of Auckland UniServices, supporting technology transfer and commercialization.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Foundation for Innovative New Diagnostics (FIND): Swiss-based global health nonprofit accelerating diagnostic development for poverty-related diseases. Adjacent in the global health PDP ecosystem with overlapping donor base (GHIF, Wellcome) and WHO partnership, though focused on diagnostics rather than therapeutics.
• Innovative Vector Control Consortium (IVCC): Product development partnership focused on vector-control products for malaria and other NTDs. Comparable PDP structure and NTD focus, though specializing in vector control rather than therapeutics like MDGH.

Broad incumbents

• PATH: Large global health nonprofit spanning vaccine development, diagnostics, and health systems across 70+ countries. Overlapping capability around NTD/rotavirus programs and clinical trial infrastructure, though materially larger and more diversified than MDGH.
• Eisai Co., Ltd. Japanese pharmaceutical company with explicit neglected disease drug donation programs (DEC for lymphatic filariasis) and FDA-approved NTD treatments. Comparable in being a for-profit company with commercial pipeline that allocates capacity to NTDs — same therapeutic area, different operating model.
• GSK (GlaxoSmithKline) — Global Health Programmes: Multinational pharmaceutical company with major neglected disease donation programs (albendazole for lymphatic filariasis and soil-transmitted helminths). Targets the same disease areas as MDGH and donates through WHO/MDA channels, though as part of a much larger commercial portfolio.

Direct peers

• Coalition for Epidemic Preparedness Innovations (CEPI): Global partnership financing and coordinating vaccine development against epidemic threats. Comparable in being a mission-driven, multi-donor R&D vehicle with a clinical-stage portfolio targeting diseases with limited commercial markets.
• TB Alliance: New York-based not-for-profit PDP developing and delivering improved tuberculosis treatments, with FDA-approved pretomanid and ongoing regimens. Operationally identical to MDGH: NGO structure, grant/Foundation funding, late-stage clinical development, and FDA-approved assets for low-income disease burden.
• International Vaccine Institute (IVI): Seoul-based international organization dedicated to vaccine discovery, development, and delivery for global health, especially in low-income countries. Directly comparable given MDGH's RV3 rotavirus vaccine program and Phase 1-3 clinical trial operations.
• Drugs for Neglected Diseases initiative (DNDi): Geneva-based not-for-profit product development partnership developing new treatments for neglected tropical diseases including leishmaniasis, Chagas disease, sleeping sickness, and mycetoma. Same PDP model, same disease focus on NTDs, same grant/donor funding structure, making DNDi the most direct comparable to MDGH.
• Medicines for Malaria Venture (MMV): Swiss-based PDP focused exclusively on discovering, developing, and delivering antimalarial medicines. Closely analogous operating model to MDGH — grant-funded, registered entity in multiple jurisdictions, clinical-stage pipeline delivering for low-income endemic populations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MedicinesDev

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicines Development Ltd.